Clinical Trial: Hepatic Arterial Infusion Chemotherapy (HAIC) Combined with Durvalumab and Lenvatinib in Patients with Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)

U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT06859684) titled 'Hepatic Arterial Infusion Chemotherapy (HAIC) Combined with Durvalumab and Lenvatinib in Patients with Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)' on Feb. 27.

Brief Summary: At present, the first-line treatment for patients with advanced unresectable intrahepatic cholangiocarcinoma is mainly systemic treatment, but the improvement in efficacy is limited and is not enough to meet the current clinical treatment needs. Hepatic artery infusion chemotherapy (HAIC) has the advantages of increasing local drug concentration and reducing toxic side effects compared to systemic intravenous...